Clinical Efficacy of Capecitabine and Cyclophosphamide (XC) in Patients with Metastatic Breast Cancer by Shien, Tadahiko et al.
Clinical Efficacy of Capecitabine and Cyclophosphamide (XC)  
in Patients with Metastatic Breast Cancer
Tadahiko Shien＊,  Hiroyoshi Doihara,  Keiko Nishiyama,  Hiroko Masuda,   
Tomohiro Nogami,  Hirokuni Ikeda,  and Naruto Taira
Department of Breast and Endocrine Surgery,  Okayama University Hospital,  Okayama 700-8558,  Japan
Combined low-dose therapy of oral capecitabine (Xeloda) and cyclophosphamide (XC) has been demon-
strated to be useful for long-term control of lesions in patients with metastatic breast cancer (MBC) 
and is aimed at symptomatic alleviation and prolongation of survival.  Here,  a retrospective review 
was conducted of MBC patients administered XC at the Okayama University Hospital (OUH),  to 
evaluate responses to XC,  adverse events and time to progression (TTP).  Twenty patients with MBC 
received XC between 2006 and 2009.  With the exception of 2 elderly patients who were over the age of 
70 at the initial examination,  all of the patients had received prior treatment with an anthracycline 
and/or a taxane.  No complete response (CR) cases were observed,  but partial response (PR) was 
achieved in 6 patients (30ｵ) and SD in 9 (45ｵ),  of whom 5 (20ｵ) sustained SD status for ｧ12 months.  
The median TTP was 6 months (range: 3-27 mo. ).  Three patients developed Grade 3 adverse events 
(diarrhea,  nausea and stomatitis),  but no other patients developed adverse reactions causing interrup-
tion of the therapy.  XC was safe even in previously treated and elderly MBC patients; moreover,  it 
yielded remarkable clinical responses.
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ith advances in the development of new drugs in 
recent years,  an expanded repertoire of phar-
macotherapeutic strategies has become available for 
breast cancer.  As molecular-targeting drugs become 
more widespread,  pharmacotherapy has become 
increasingly more eﬀective but also more complex.  
The selection of drugs must be based on results of 
individual drug sensitivity assessments.  In the case of 
breast cancer treatment,  in particular,  the most suit-
able therapeutic regimens should be selected not only 
based on assessment of the indication for hormone 
therapy or for the molecular-targeting drug trastu-
zumab by determining the estrogen receptor (ER) and 
HER2 expression status,  but also by taking into 
account the tumor characteristics,  such as the malig-
nancy grade,  extent of lymph node metastasis,  and 
sites of distant metastasis through translational 
research which has been applied extensively in recent 
years.  Risk factors such as adverse reactions,  cost,  
and the social environment of the patients are also of 
importance in this determination.  In particular,  treat-
ment for recurrent carcinoma of the breast is still 
aimed primarily at prolongation of survival and alle-
viation of symptoms rather than at cure of the malig-
nancy,  so that the weight of each of these factors 
diverges widely from that during the consideration of 
adjuvant chemotherapy,  which is aimed at cure.  It 
sum,  theoretical and clinical evidence-based evaluation 
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of the risk versus beneﬁt of various therapeutic strate-
gies on a patient-by-patient basis has been increasingly 
expected in recent years.
　 Patients with recurrent breast cancer present with 
diverse symptoms depending on the site(s) of the meta-
static lesions and exhibit anxiety about exacerbation 
of the condition.  Many are elderly and inevitably 
require familial support.  Drugs that can be used 
safely and eﬀectively for prolonged periods of time in 
such patients are still very few.
　 This study was undertaken as a retrospective 
evaluation of the clinical eﬃcacy of and adverse reac-
tions to XC therapy,  one of the treatment options 
employed for recurrent breast cancer,  consisting of 
capecitabine (Xeloda,  X) and cyclophosphamide (C),  
both available in oral formulations.
Patients and Methods
　 Patients. A retrospective analysis was per-
formed of patients with MBC who received combined 
capecitabine and cyclophosphamide therapy (XC) 
between December 2004 and March 2009 at Okayama 
University Hospital (OUH).  The patient population 
was identiﬁed from a database at the Division of 
Breast and Endocrine surgery.  They were followed up 
until death or,  if still alive,  until their last visit up to 
March 2009.
　 Baseline evaluation included clinical examination,  
chest X-ray,  CT,  nuclear bone scan,  and biochemical 
and hematological tests.  The complete blood count and 
biochemical tests were repeated every 21 days.  The 
best response in each patient was assessed according 
to the WHO criteria.  Complete response (CR) was 
deﬁned as disappearance of all clinical and radio-
graphic evidence of the tumor as assessed on two 
occasions at least 4 weeks apart.  Partial response 
(PR) was deﬁned as a 30ｵ or greater decrease in the 
sum of the maximum perpendicular diameters of mea-
surable lesions.  Stable disease (SD) was deﬁned as a 
less than 30ｵ decrease but greater than 25ｵ 
increase in the sum of the bi-perpendicular diameters 
of measurable lesions and the absence of the appear-
ance of new lesions; these conditions had to be main-
tained for at least 12 weeks to be labeled as SD,  and 
SD maintained for over 40 weeks was deﬁned as pro-
longed SD.  Progressive disease (PD) was deﬁned as 
a greater than 25ｵ increase in the sum of bi-perpen-
dicular diameters of measurable lesions,  or the 
appearance of new lesions.  The clinical beneﬁt rate 
was deﬁned as the proportion of patients in whom a 
CR,  PR or prolonged SD was achieved.  The National 
Cancer Institute common terminology criteria for 
adverse events (CTCAE) version 2.0 [1] were adopted 
to determine the toxicity of the treatment.
　 Evaluation of pathological factors. Surgical 
specimens were sectioned at 7-10mm for evaluation of 
the pathological response by pathologists.  Expression 
levels of ER (1D5,  Dako Cytomation,  Glostrup,  
Denmark),  PgR (1A6,  Novocastra),  and HER2 
(HercepTest®,  Dako Cytomation) were examined by 
immunohistological staining.  The ER and PgR status 
was labeled as positive when greater than 10ｵ of the 
cancer cell nuclei exhibited positive staining,  regard-
less of the staining intensity.  HER2 expression was 
scored as follows: (0),  no positive cell staining; (1＋),  
slightly positive in more than 10ｵ of the cancer 
cells; (2＋),  moderately positive in more than 10ｵ of 
the cancer cells; and (3＋),  markedly positive in more 
than 10ｵ of the cancer cells.  Immunohistochemistry 
(IHC) scores of (2＋) or (3＋) were deﬁned as HER2-
positive.
　 Treatment. Capecitabine (1,600 or 2,400mg/
day) and cyclophosphamide (100mg/day) (XC) were 
administered orally twice daily for 2 weeks,  followed 
by a week of treatment cessation.  Treatment was 
continued until disease progression,  appearance of 
unacceptable adverse events or withdrawal of the 
patientʼs consent.  In the case of Grade 2 or worse 
toxicity,  XC administration was interrupted and 
resumed only after the toxicity had resolved entirely 
or improved to Grade 1.
　 The time to progression (TTP) was calculated from 
the day of commencement of XC administration until 
the day of documented progression.  Overall survival 
(OS) was calculated from the start date of XC therapy 
to the date of death from any cause.  TTP and OS 
were analyzed according to Kaplan-Meier estimates.
Results
　 Twenty MBC patients received XC therapy 
between December 2004 and March 2009 at OUH.  
Three of these patients were still receiving XC at the 
last follow-up.  Table 1 shows the patient characteris-
tics.  The median age was 56 (29-83) years.  The 
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Eastern Cooperative Oncology Group (ECOG) perfor-
mance status of the patients was ＜2 in all patients.  
The site of metastatic disease was the bone and/or 
soft tissue in 5 patients (25ｵ) and a visceral site(s) 
(lung,  liver,  brain and pleura) in 15 patients (75ｵ).  
Table 2 shows the chemotherapy regimens that the 
patients had received prior to the XC therapy.  The 
median number of chemotherapy regimens used before 
the XC regimen was 2 (0-5).  All except 2 patients 
who were older than 70 years old had received an 
anthracycline and/or a taxane.  Three patients (15ｵ) 
had received vinorelbine and 5 (25ｵ) had received a 
5FU derivative prior to the XC therapy.  Prior oral 
formulations received included CMF (2 patients),  
capecitabine alone (2 patients) and S-1 (1 patient).  
Eleven (55ｵ) patients were ER-positive and had 
received hormone therapy prior to the XC treatment.  
Three patients (15ｵ) with HER2-positive disease had 
received trastuzumab in combination with a taxane or 
vinorelbine before the XC treatment,  and 2 had 
received XC with trastuzumab.
　 The response rate (RR) was 30ｵ,  with none of the 
patients showing clinically complete response (CR) and 
30ｵ (6/20) showing PR.  Nine patients (45ｵ) 
showed SD,  and prolonged SD with continued XC 
administration for more than 12 months was observed 
in 4 (20ｵ) patients (Table 3).  The overall clinical 
beneﬁt rate (CR,  PR and prolonged SD) was 50ｵ 
(10/20).  Six out of the 10 patients with clinical ben-
eﬁt had visceral involvement (liver,  4; lung,  2),  and 
75ｵ (3/4) of the patients who showed prolonged SD 
had bone metastasis only.  Six out of the 10 patients 
were ER-positive and one was HER2-positive.  Four 
of the patients had triple-negative breast cancer,  
being negative for ER,  PgR and HER2,  and the 
response rate to XC in these patients was relatively 
high (PR 2,  prolonged SD 1 and SD 1).  Two of the 
patients who had received capecitabine alone before 
the XC treatment showed SD.  The median TTP was 
6 months (range,  1-27 months; Fig.  1).  The median 
OS from the start of treatment for the metastases 
was 38 months (range,  9-86 months),  and 6 patients 
(30ｵ) were still alive at the last follow-up.
　 Overall,  the XC regimen was relatively well-toler-
ated.  Table 4 shows the adverse events that were 
encountered in the patients treated with XC.  Grade 3 
toxicities were observed in 3 patients (diarrhea,  
2; nausea,  1; stomatitis,  1).  There was no case of 
hand-foot syndrome or febrile neutropenia,  and none 
of the XC-related adverse events were fatal.  The 
most frequent reason for treatment discontinuation 
was disease progression (14 patients,  82ｵ).  The XC 
treatment was discontinued and other chemotherapy 
started in the 3 patients who showed Grade 3 adverse 
events.  One of the 2 relatively older patients (73 and 
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Table 1　 Patient characteristics
No. of patients
(n＝20) % of patients
Median age (years; range) 56 (29-83)
Metastatic site(s) involved
　Bone/soft tissue  5 25
　Visceral 15 30
Histology
　Invasive ductal carcinoma 19 95
　Invasive lobular carcinoma  1  5
Estrogen receptor status
　Positive 11 55
　Negative  9 45
HER2/neu status
　Positive  5 25
　Negative 15 75
Table 2　 Prior chemotherapy
Prior chemotherapy No. of patients(n＝20) % of patients
No. of regimens used
0/1/2/3/4/5 2/5/7/3/2/1
Median 2 (0-5)
　Anthracycline 16 80
　Taxane 14 70
　Vinorelbine  3 15
　Capecitabine  2 10
　S-1  1  5
　Trastuzumab  3 15
Table 3　Response rate
Response No. of patients(n＝20) % of patients
CR 0  0
PR 6 30
SD 9 45
Prolonged SD (＞12 months) 4 20
PD 5 25
CR,  complete response; PR,  partial response; SD,  stable 
disease; PD,  progressive disease.
83 y.o. ) who were administered XC as ﬁrst-line che-
motherapy showed PR and the other showed prolonged 
SD without the development of adverse events.
Discussion
　 Following its administration,  capecitabine (X) is 
converted to its active form 5-FU by thymidine phos-
phorylase (TP),  which occurs at high levels in tumor 
tissues,  to exert its antitumor eﬀect [2].  Disease 
control with X treatment alone has been reportedly 
achieved in 57-63ｵ of patients with anthracycline- 
and taxane-refractory,  recurrent breast cancer,  with 
a median survival time of about 1 year [3-5].  The 
higher the level of TP activity in the tumor tissues,  
the greater the clinical beneﬁt obtained with X ther-
apy [6]; concomitant use of a drug(s) enhancing the 
TP activity in the tumor tissues may augment the 
therapeutic eﬀect of this drug.  It has been reported 
that besides paclitaxel,  docetaxel and mitomycin C 
administration,  cyclophosphamide administration is 
also associated with elevation of the intratumoral TP 
activity [7-10].  Several clinical trials of combined 
therapy with capecitabine and paclitaxel or docetaxel 
have been conducted,  with good results,  demonstrat-
ing the superiority of the combined therapeutic regi-
mens [3,  4,  11-14].  In particular,  a study designed 
to compare the results of treatment with X ＋ doc-
etaxel and docetaxel alone in patients with recurrent 
breast cancer previously treated with anthracyclines 
showed that the combined regimen was signiﬁcantly 
superior in terms of the response rate and response 
duration,  as well as the survival time [11].  Several 
clinical studies have been published on the usefulness 
of combined treatment with molecular-targeting thera-
peutic agents.  Use of these drugs in the treatment of 
recurrent breast cancer,  however,  is still controver-
sial,  because of the signiﬁcant adverse reactions and 
unusually high prices of these drugs,  the as-yet insuf-
ﬁcient assessment of the therapeutic responses,  and 
the fact that the patientʼs disease status,  social back-
ground,  etc.,  must be taken into account when pre-
scribing them.
　 As for the adverse reactions to X,  symptoms 
related to the gastrointestinal system and myelosup-
pression are relatively mild,  while hand-foot syndrome 
has been reported to occur at a high frequency.  In the 
present case series,  none of the patients developed 
hand-foot syndrome.  Myelosuppression may occur also 
as an adverse reaction to C but there was no patient 
in the present case series with febrile neutropenia or 
bone marrow suppression necessitating treatment 
discontinuation.  In 3 patients (15ｵ),  adverse reac-
tions necessitated discontinuation of treatment and a 
switch to other therapeutic regimens; in all 3 patients,  
the adverse reaction pertained to the gastrointestinal 
system.  Measures to prevent these gastrointestinal 
reactions should be taken from the outset.  In the 
present case series,  with the patient age reaching up 
to 83 years,  XC therapy proved to be safe,  raising no 
concerns in terms of adverse reactions.  Thus,  XC 
therapy is a remarkably well tolerated and safe treat-
ment.  Furthermore,  it is considered that XC therapy 
may be safely and eﬀectively employed for the treat-
ment of breast cancer in elderly subjects for whom a 
deﬁnitive treatment policy is yet to be established.
　 The advantage of orally available medications lies 
ﬁrst in their milder adverse reactions and greater 
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Table 4　 XC-treatment-related adverse events
event Grade 1/2 (%) Grade 3 (%)
Diarrhea 0 　 1 ( 5 )
Anorexia 1 (5) 0 　
Nausea/vomiting 0 　 2 (10)
Stomatitis 0 　 1 ( 5 )
Generalized fatigue 1 (5) 0 　
Hand-foot syndrome 0 　 0 　
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Fig. 1　 Time to progression curve of metastatic breast cancer 
patients treated with Capecitabine and Cyclophosphamide (XC).
patient compliance,  which allow a good QOL to be 
maintained.  As the aims of treatment in patients with 
recurrent breast cancer are prolongation of survival 
and alleviation of symptoms,  combinations of drugs 
must be carefully chosen for a therapeutic strategy for 
maintaining patient QOL.  Currently,  treatment with 
capecitabine alone is undertaken in a number of 
patients with recurrent breast cancer,  and this ther-
apy is generally thought to be beneﬁcial for mainte-
nance of a good QOL.  The XC therapy in the present 
series consisted of X in combination with a low dose 
of C.  According to a report by Harvey V et al.,  XC 
therapy was superior by 12.6ｵ in terms of the clinical 
response to treatment with capecitabine alone [15].  In 
regard to adverse reactions,  neutropenia associated 
with C was noted in the XC therapy group; however,  
there were no other signiﬁcant intergroup diﬀerences.  
There has been no large-scale prospective study pub-
lished to date,  so that further investigation is war-
ranted to clarify any diﬀerences in survival [7-8,  
16].  In the present case series also,  partial response 
were obtained in 30ｵ of all the patients,  including 
patients with a history of prior treatment.  
Furthermore,  for the ﬁrst time,  it has been docu-
mented that 20ｵ of the patients showed a prolonged 
duration of SD that was sustained for ｧ1 year.  These 
responses seem to be largely attributable to the met-
ronomic therapeutic eﬀect obtained with the use of the 
combined XC regimen [2,  7].  XC therapy,  when 
viewed from these viewpoints,  may yield responses as 
satisfactory as those of hormonal therapy,  with a 
long-sustained QOL; therefore,  its institution from an 
early stage of treatment is expected to be of signiﬁ-
cance especially in patients with breast cancer not 
showing adequate response to hormonal therapy.
　 In recent years,  the development of an eﬀective 
therapeutic strategy for dealing with basal-like carci-
noma of the breast,  which is recognized as a highly 
malignant type with an unfavorable prognosis,  has 
drawn increasing attention [17].  This type of breast 
cancer has been shown to involve mutations of BRCA-
1,  so that genetic instability is likely implicated in its 
pathogenesis.  Further,  it has been documented as 
being refractory to currently available drugs,  and no 
standard treatment has been established yet.  There is 
the possibility,  however,  that alkylating agents such 
as C,  which directly act upon DNA strands to cause 
inter-strand linking,  may prove eﬀective against it.  
Therefore,  orally available C preparations are cur-
rently the focus of attention for the treatment of these 
breast tumors,  and results of relevant studies are 
eagerly awaited.  The present study data suggest the 
potential usefulness of XC therapy in the treatment of 
triple-negative breast carcinomas,  in that the therapy 
yielded PR in 50ｵ of the patients with triple-negative 
breast carcinoma,  albeit there were only ４ such 
patients.  However,  there is no established therapeutic 
strategy using these drugs for the treatment of early 
drug-resistant triple-negative breast carcinomas.  
These treatment regimens continue to be instituted 
only after the standard use of anthracyclines and tax-
anes,  as is the case with other types of breast cancer.  
Further investigations are needed to select the most 
eﬀective treatment method with prior scrutiny of the 
tumor susceptibility to drugs.  It seems very likely that 
XC therapy would serve as an important treatment 
alternative under these circumstances.
　 The therapeutic concept of inhibition of tumor 
growth by inhibiting peritumoral neomicrovasculariza-
tion to produce a resting state of neoplastic growth is 
referred to as metronomic chemotherapy [18].  
Laboratory studies have demonstrated the anti-
neoangiogenic and antitumor eﬀects of long-term 
administration of C at low doses [19].  This concept 
has been clinically applied,  and reports have been 
appearing in the literature,  including one study in 
which low-dose C was used concomitantly with hor-
monal therapy [20] and more recently,  trials of 
combined treatment with molecular-targeting drugs 
that inhibit neovascularization,  with the expectation 
of antiangiogenic eﬀects [21-22].  There has been a 
growing trend of devising therapeutic strategies based 
on the same concept for other solid tumors as well as 
breast cancer [23].  The XC therapy reported herein 
also represents a regimen for metronomic chemother-
apy aimed at long-sustained inhibition of tumor growth 
via combined use of low-dose C and X,  which enhances 
the eﬀect of the former.  These therapeutic regimens 
may be said to be useful inasmuch as an anti-neoangio-
genic eﬀect can be expected from both regimens; in 
addition,  as both drugs are available for oral adminis-
tration,  long-term safe use with well-maintained com-
pliance is more likely.  In the present study,  the inci-
dence of adverse reactions was remarkably low; as 
expected,  the therapeutic regimen was well-tolerated 
even in elderly patients over the age of 70 years,  with 
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remarkable drug eﬀects.  In particular,  the prolonged 
duration of SD of ｧ1 year observed in 20ｵ of the 
treated patients may be said to exemplify the concept 
of metronomic chemotherapy.  Future incorporation of 
newer molecular-targeting therapeutic agents,  besides 
expanding the available spectrum of therapeutic 
options,  will undoubtedly allow more eﬀective therapy 
to be individualized according to the patientʼs back-
ground characteristics,  taking into account the biology 
of the breast cancer.  Research to elucidate the biol-
ogy of breast cancer and the accumulation of pertinent 
cases and prospective studies are necessary in the 
future.
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